[HTML][HTML] Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M Reck, F Barlesi, CI Henschke, D Isla, S Stiebeler… - Annals of oncology, 2012 - Elsevier
Background Bevacizumab is a monoclonal antibody against vascular endothelial growth
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M Reck, F Barlesi, L Crinò… - Annals of oncology …, 2012 - pubmed.ncbi.nlm.nih.gov
Background Bevacizumab is a monoclonal antibody against vascular endothelial growth
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
[引用][C] Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M Reck, F Barlesi, L Crinò, CI Henschke, D Isla… - Annals of …, 2012 - cir.nii.ac.jp
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated
with bevacizumab: a consensus report from a panel of experts | CiNii Research CiNii 国立 …
with bevacizumab: a consensus report from a panel of experts | CiNii Research CiNii 国立 …
[HTML][HTML] Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M Reck, F Barlesi, L Crinò, CI Henschke, D Isla… - Annals of …, 2012 - ncbi.nlm.nih.gov
Background: Bevacizumab is a monoclonal antibody against vascular endothelial growth
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
[PDF][PDF] Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M Reck, F Barlesi, L Crino, CI Henschke… - Annals of …, 2012 - pdfs.semanticscholar.org
Background: Bevacizumab is a monoclonal antibody against vascular endothelial growth
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
[PDF][PDF] Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M Reck, F Barlesi, L Crino, CI Henschke… - Annals of …, 2012 - scienceopen.com
Background: Bevacizumab is a monoclonal antibody against vascular endothelial growth
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M Reck, F Barlesi, L Crinò, CI Henschke… - Annals of …, 2012 - annalsofoncology.org
Background Bevacizumab is a monoclonal antibody against vascular endothelial growth
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
[引用][C] Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M RECK, F BARLESI, L CRINO… - Annals of …, 2012 - pascal-francis.inist.fr
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with
bevacizumab: a consensus report from a panel of experts CNRS Inist Pascal-Francis CNRS …
bevacizumab: a consensus report from a panel of experts CNRS Inist Pascal-Francis CNRS …
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.
M Reck, F Barlesi, L Crinò, CI Henschke… - Annals of Oncology …, 2011 - europepmc.org
Background Bevacizumab is a monoclonal antibody against vascular endothelial growth
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
[PDF][PDF] Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M Reck, F Barlesi, L Crino, CI Henschke, D Isla… - Annals of …, 2012 - researchgate.net
Background: Bevacizumab is a monoclonal antibody against vascular endothelial growth
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …
factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event …